Previous 10 | Next 10 |
2024-04-04 11:12:55 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli...
2024-04-03 13:07:34 ET More on Bristol-Myers, Merck, etc. Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis) ...
Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase, along with increased durability compared to epoetin alfa This is the fourt...
Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, e...
2024-04-01 20:58:00 ET Summary Bristol-Myers Squibb has expected 2024 annual revenue of $45.85B and expected annual earnings per share of $6.83. BMY is currently below its 10-month exponential moving average (EMA), indicating bearish price action. However, there are signs of i...
2024-04-01 10:57:29 ET More on Bristol-Myers Squibb Company , Zai Lab, etc. Bristol Myers Squibb: The Comeback Is Unfolding Bristol-Myers Squibb Is Not A Buy For Me Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript)...
2024-04-01 06:08:19 ET Summary Cytokinetics' stock has seen much buyout speculation in recent months, with companies like Eli Lilly, Novartis, Johnson & Johnson, Amgen, and AstraZeneca being potential suitors. The company's Phase 3 study for aficamten, a treatment for heart di...
2024-04-01 03:44:47 ET Summary I rank a selection of Dividend Radar stocks and present the ten top-ranked stocks for consideration. To rank stocks, I do a quality assessment and sort stocks by quality scores, breaking ties with additional metrics. This month, I'm presenting ca...
2024-03-31 04:49:02 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-03-29 10:45:03 ET Bristol-Myers Squibb Co. (BMY) BMY is trading UP for the last 5 days, and it at trading at $54.28 with volume of 9,234,665 and a one day change of $1.02 (1.92%). Bristol-Myers Squibb Co. has a 52-week low of 47.58 and a 52-week high of $71.07. The business's 5...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...